---
title: "GeoVax Labs Raises $863K Via Warrant Exercise Inducement; Issues New 5-Year Warrants at $1.36"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/281249755.md"
description: "GeoVax Labs has raised approximately $863,000 through a warrant exercise inducement, allowing existing warrant holders to exercise 634,658 warrants at a reduced price of $1.36 per share. In return, the company will issue new warrants for up to 1,269,316 shares at the same price, valid for five years pending Nasdaq approval. A.G.P./Alliance Global Partners served as the exclusive financial advisor for this transaction, receiving a 7% fee and up to $40,000 in legal expenses."
datetime: "2026-03-31T21:23:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281249755.md)
  - [en](https://longbridge.com/en/news/281249755.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281249755.md)
---

# GeoVax Labs Raises $863K Via Warrant Exercise Inducement; Issues New 5-Year Warrants at $1.36

GeoVax Labs entered into warrant exercise inducement letters with existing warrant holders to generate immediate cash and simplify its capital structure. Holders agreed to exercise 634,658 existing warrants for cash at a reduced price of $1.36 per share, delivering approximately $863,000 in gross proceeds. In exchange, the company will issue new warrants for up to 1,269,316 shares at the same $1.36 exercise price, exercisable after required Nasdaq stockholder approval and expiring five years from issuance. GeoVax retained A.G.P./Alliance Global Partners as exclusive financial advisor, paying a 7% fee and up to $40,000 in legal expenses.

**Agreement details:**

-   **Agreement type**: Warrant exercise inducement and issuance of new common stock purchase warrants
-   **Counterparty**: Existing warrant holders
-   **Signed / Effective**: Mar 31 2026 / Apr 01 2026
-   **Duration / Termination**: 5 years from issuance
-   **Reason**: Raise cash and incentivize warrant exercises

Original SEC Filing: GeoVax Labs, Inc. \[ GOVX \] - 8-K - Mar. 31, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [GOVXW.US](https://longbridge.com/en/quote/GOVXW.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [GOVX.US](https://longbridge.com/en/quote/GOVX.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)

## Related News & Research

- [Lantern Pharma raises capital, plans AI platform spinoff](https://longbridge.com/en/news/286480334.md)
- [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)
- [GeoVax Highlights Strategic Importance of Domestic MVA-Based Preparedness Infrastructure Amid Escalating Global Infectious Disease Threats](https://longbridge.com/en/news/286807713.md)
- [ImmunityBio reports higher complete response rates for ANKTIVA plus BCG in AUA analysis](https://longbridge.com/en/news/286903126.md)
- [Full Transcript: Cellectar Biosciences Q1 2026 Earnings Call](https://longbridge.com/en/news/286422585.md)